drugset
drugset / Trial / NCT02235987

Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.

NCT02235987 ↗

Phase 2 Completed 20 enrolled Aspireo Pharmaceuticals Limited
NaSingle-groupOpen-labelTreatment

Summary

The study is designed to investigate the safety, tolerability and efficacy of DG3173 in untreated acromegaly patients. Twenty patients received ascending single doses of DG3173 and one dose of octreotide, the current gold standard of medical therapy for acromegaly, with each patient receiving all doses of DG3173 as well as octreotide.

Timeline

Start
2012-10
Primary completion
2012-12
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide 300 ug Subcutaneous
Subject veldoreotide Protein / enzyme biologic 100 ug Subcutaneous
Subject veldoreotide Protein / enzyme biologic 300 ug Subcutaneous
Subject veldoreotide Protein / enzyme biologic 900 ug Subcutaneous
Subject veldoreotide Protein / enzyme biologic 1800 ug Subcutaneous

Indications

acromegaly